Gradient Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Gradient Health provides a medical imaging data platform giving AI researchers and healthcare companies access to de-identified radiology datasets for model training and validation.
About
Gradient Health is a healthcare data company founded in 2019 that operates a platform providing access to de-identified medical imaging data for AI development, research, and regulatory validation. The company partners with health systems and imaging centers to source, de-identify, and structure radiology datasets including X-rays, CT scans, MRI studies, and pathology images that AI developers need to train and validate clinical algorithms. Obtaining sufficient high-quality labeled medical imaging data has been one of the primary bottlenecks for AI medical imaging companies, and Gradient Health addresses this by creating a market for compliant data access. The company uses advanced de-identification techniques that go beyond HIPAA minimum requirements to ensure patient privacy while preserving the clinical detail that makes datasets useful for AI training. Gradient serves medical imaging AI companies, pharmaceutical companies conducting imaging biomarker research, and academic medical centers building AI models. The company has built relationships with health systems across the US and has assembled imaging datasets spanning millions of studies across diverse patient populations and imaging equipment types.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.